Researchers at the Ecole Polytechnique Federale de Lausanne (EPFL) have developed an artificial intelligence-driven deep brain stimulation (DBS) system that automatically adjusts to a patient’s movement in real time. According to a study published in Nature Medicine, this technology improves mobility for Parkinson’s disease patients by decoding neural biomarkers to modulate electrical pulses during activities like walking, climbing stairs, or standing.
How does AI-driven DBS improve Parkinson’s treatment?
Conventional DBS systems deliver a continuous, fixed electrical pulse to the brain, which often fails to address gait impairments—the walking difficulties frequently experienced by Parkinson’s patients. The new system, developed by researchers at EPFL and CHUV, uses AI to bridge this gap. By analyzing neural signals from forty participants, the system identifies specific locomotor states and adjusts stimulation levels within seconds. According to Eduardo Moraud, a professor at EPFL, this allows the therapy to match the physiological demands of different movements, such as turning or navigating obstacles, helping patients move with greater natural fluidity.
Deep brain stimulation has been a standard treatment for Parkinson’s motor symptoms for over three decades, with more than 200,000 patients worldwide currently using the technology.
What are the primary differences between conventional and adaptive DBS?
The core difference lies in the responsiveness of the stimulation. Traditional DBS operates on a “one-size-fits-all” approach, providing a steady stream of electricity regardless of the patient’s immediate physical activity. In contrast, the adaptive system functions as an “intelligent therapy.” Jocelyne Bloch, head of neurosurgery at CHUV, notes that because walking problems respond differently to stimulation than tremors or rigidity, the ability to adjust settings automatically represents a shift in clinical strategy. While conventional DBS treats the disease’s general state, adaptive DBS treats the patient’s specific, moment-to-moment actions.
What comes next for adaptive neurotechnology?
The research team, working within the .NeuroRestore center, is currently planning follow-up studies to assess the long-term clinical outcomes of this adaptive approach. The goal is to scale the technology for a larger patient population. By partnering with industry leader Medtronic, the researchers have refined the system to ensure it can transition from a clinical environment to everyday use. The next phase of development will focus on verifying that these real-time adjustments remain effective and safe over extended periods of daily life.
Frequently Asked Questions
Is this technology available for all Parkinson’s patients?
Currently, the system is part of a research study involving forty participants. Further trials are required before it becomes widely available for general clinical use.
Does the system require manual adjustment by the patient?
No. The system uses AI-powered neural decoders to interpret brain activity, allowing the stimulation to adjust automatically without the patient needing to change settings manually.
What specific symptoms does this improve?
The therapy is designed to address gait impairments, including difficulties with walking, climbing stairs, and standing up, which are often not fully resolved by traditional, fixed-parameter DBS.
If you are interested in the latest advancements in neurotechnology, subscribe to our monthly research newsletter to receive updates on clinical trials and breakthroughs in Parkinson’s care.
Have you or a loved one experienced challenges with traditional Parkinson’s treatments? Share your thoughts in the comments section below or explore our archive of neurology research for more in-depth reports.
